Introduction
Curcumin (CUR), also known as diferuloylmethane (IUPAC name (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), is the main polyphenol in turmeric (Curcuma longa L.). CUR is known to exhibit a wide range of effects including anti-inflammatory, antitumor, and lipid-lowering activities, which are attributed primarily to its potent antioxidant capacity. [1] [2] [3] However, CUR's ability to exert these biological effects in vivo is undermined by its low bioavailability due to 
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harigae et al poor intestinal absorption and rapid metabolism. [4] [5] [6] CUR's low bioavailability in vivo was confirmed by our previous work in which CUR absorbed through the intestinal cells of rats was predominantly conjugated as curcumin glucuronide (CURG) and low levels of unmetabolized CUR were found in the blood. 7, 8 We hypothesized that encapsulating CUR with poly-(lactic-co-glycolic acid) (PLGA)-based nanoparticles would enhance the bioavailability of CUR administered orally because of PLGA's ability to disperse in water, pass through the gut, bypass first-pass metabolism, and endure the harsh external conditions of the gastrointestinal tract (chemical and enzymatic degradation). 4, [9] [10] [11] [12] [13] Our hypothesis is supported by previous studies that reported that encapsulated CUR with PLGA-based nanoparticles administrated orally to rats increased CUR levels in the plasma. [14] [15] [16] [17] [18] However, to the best of our knowledge, there are no data about CURG, despite the fact that it is the main metabolite of CUR found in the plasma. Therefore, it is not clear whether CUR nanoparticles (CUR-NP) actually improve the intestinal absorption of CUR.
In this study, we aimed to evaluate whether orally administered PLGA-based nanoparticles improved the bioavailability of CUR. We prepared PLGA-based CUR-NP by solvent evaporation. Following oral administration of CUR-NP to rats, we determined the levels of CURG and CUR in the plasma and organs (eg, kidney and liver) using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). After confirming that intestinal absorption of CUR-NP was higher than nonencapsulated CUR, we sought to determine the cause of increased intestinal absorption of CUR-NP by examining micellar solubilization of CUR-NP and CUR in mixed micelles comprised of phosphatidylcholine (PC) and bile salts in vitro. In addition, we investigated the cellular uptake of micelles in differentiated Caco-2 human intestinal cells. Overall, this study provides a better understanding of the bioavailability of CUR and CUR-NP administered orally, which may lead to novel discoveries in food function and disease prevention.
Materials and methods Materials
CUR was purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). CURG was purchased from Toronto Research Chemicals (Toronto, ON, Canada). PLGA (50:50, molecular weight =30,000-60,000 g/mol), polyvinyl alcohol (PVA, molecular weight =30,000-70,000 g/mol, 87%-90% hydrolyzed), and egg yolk PC (purity $99%) were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Taurocholic acid sodium salt (purity $98%) was purchased from Nacalai Tesque (Kyoto, Japan). All other chemicals and reagents used were of analytical grade or higher.
Preparation of cUr-NP
CUR-NP was prepared by solvent evaporation. 19 Briefly, 20 mg of CUR and 200 mg of PLGA were dissolved in 2 mL of dichloromethane as an oil phase. Next, 4 mL of 5% (w/v) PVA aqueous solution was added and vortexed. The organic-aqueous mixture was sonicated at 40% amplitude for 2 minutes using a sonic dismembrator and then added dropwise to 100 mL of 0.3% (w/v) PVA aqueous solution under rapid stirring. The resultant oil-in-water emulsion was stirred overnight in a fume hood to allow the dichloromethane solvent to evaporate. The suspension was centrifuged (2,000× g, 10 minutes, 4°C) to remove larger aggregates and CUR not wrapped in the CUR-NP. The supernatant was collected, filtered (Millex-HV, 0.45 μm, 33 mm; EMD Millipore, Billerica, MA, USA), washed twice with Milli-Q water by centrifugation, and finally resuspended in 2 mL of 1% (w/v) sucrose aqueous solution. The CUR-NP suspension was lyophilized and stored in the dark at -30°C.
Nanoparticles characterization
Approximately 5 mg of CUR-NP (lyophilized powder) was resuspended in 5 mL of distilled water. The suspension was analyzed by dynamic light scattering and laser Doppler anemometry using ELS-Z (Otsuka Electronics Co., Ltd, Osaka, Japan) to determine the mean diameters, polydispersity index (PDI), and zeta potentials.
To measure the entrapment efficiency (EE) and the loading efficiency (LE), lyophilized CUR-NP (~10 mg) was dissolved in 10 mL of methanol and sonicated to extract CUR. The solution was then centrifuged (1,000× g, 10 minutes, 4°C), and the supernatant was collected. The amount of CUR in the extract was determined by HPLC-UV. Specifically, a ProC18 column (4.6×150 mm, 5 μm; YMC Co., Ltd, Kyoto, Japan) was used, and the extract was eluted using a binary gradient consisting of the following HPLC solvents: (A) 0.05% formic acid and (B) acetonitrile. The gradient profile was as follows: B linear ratio; 30%-50% at 0-17 minutes, 50%-100% at 17-22 minutes, and 100% at 22-32 minutes. The flow rate was adjusted to 1 mL/min, and the column temperature was maintained at 40°C. The column eluent was sent to a UV detector (UV-2075 PLUS; Jasco, Tokyo, Japan) for CUR monitoring at 420 nm. The concentration of CUR was calculated using the equation corresponding to the standard 
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Metabolic fate of Plga-based curcumin nanoparticles curve. EE was calculated as follows: EE (%) = CUR encapsulated / CUR total ×100, and LE was calculated as follows: LE (%) = CUR encapsulated /CUR-NP total ×100.
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Surface morphology of CUR-NP (lyophilized powder) was evaluated by scanning electron microscope (SEM; SU8000 Type II, Hitachi Ltd, Tokyo, Japan) and transmission electron microscope (TEM; H-7650 ZeroA, Hitachi Ltd). Lyophilized CUR-NP powder (containing 3 mg CUR) was suspended in 10 mL of distilled water and photographed. CUR (3 mg) was also photographed.
animal study
Male Sprague Dawley rats (6 weeks of age, 150-190 g body weight) were purchased from CLEA Japan Inc. (Tokyo, Japan) and housed in cages kept at 24°C with a 12-hour light:dark cycle. The rats were acclimated with commercial rodent chow (CE-2; CLEA Japan Inc.) and water for 1 week. After acclimation, rats were fasted for 16 hours and received CUR (100 mg/kg) by oral gavage using 1% sodium cholate as a vehicle. Similarly, CUR-NP was administrated to rats at a dose equivalent to 100 mg CUR/kg using 1% polysorbate 80 (PS80; Nihon Yushi Co., Ltd, Tokyo, Japan) as a vehicle. Blood samples (~0.3 mL) were collected into heparinized tubes from the jugular vein at 0, 0.5, 1, 1.5, 3, 6, and 24 hours following oral administration and centrifuged (1,000× g, 15 minutes, 4°C) to prepare the plasma samples. In a separate study, the liver and kidney were excised at 1.5 hours after oral administration of CUR or CUR-NP. Harvested plasma and organs were stored at -80°C until further analysis. These protocols were reviewed by the Committee on the Ethics of Animal Experiments and carried out in accordance with the Animal Experiment Guidelines of Tohoku University (Sendai, Japan). The permit number for this animal experiment is 2015-Noudou-015.
extraction from samples
Plasma (100 μL) was mixed with 200 μL of methanol by vortexing and then centrifuged (5,000× g, 5 minutes, 4°C). The supernatant was collected, mixed with 500 μL of water, and then loaded onto an Oasis HLB 1 cc cartridge (Waters, Milford, MA, USA). The cartridge was washed with 1 mL of water, and the curcuminoids (CUR, CURG, and other metabolites) were eluted with 2 mL of methanol. Organs were homogenized with saline (containing 1 mM ethylenediaminetetraacetic acid) to prepare 30% (w/v) homogenate solution. Curcuminoids in the homogenate solution (100 μL) were extracted in a manner similar to that of plasma. The extracts were dried and redissolved in 1 mL of methanol.
Aliquots of extracts were injected onto an XBridge™ C18 column (2.1×150 mm, 3.5 μm; Waters) maintained at 40°C. The mobile phase consisted of two components: (A) 0.05% formic acid and (B) acetonitrile. The gradient profile was as follows: 0-20 minutes 85%-0% A linear. The flow rate was 0.2 mL/min. Curcuminoids were analyzed using 4000 QTRAP HPLC-MS/MS (AB Sciex, Foster City, CA, USA). MS/MS parameters of CUR, CURG, and tetrahydrocurcumin (THC, purity $95%; Sigma-Aldrich Co.) were optimized with their respective standards under electrospray ionization (negative). The parameters were as follows: turbo gas temperature, 600°C; spray voltage, -4,000 V; nebulizer gas, 30 psi; auxiliary gas, 30 psi; curtain gas, 20 psi; collision gas, 6.0. CUR, CURG, and THC were detected using multiple-reaction monitoring ( 
Micellar solubilization study
Mixed micelles, comprised of PC and bile salts containing either CUR (CUR-MM) or CUR-NP (NP-MM), were prepared as previously described. 21 Briefly, micellar solutions were composed of 9.9 mM taurocholic acid sodium salt, 0.9 mM egg yolk PC, 1.5 mM oleic acid, 0.75 mM 1-oleoyl-rac-glycerol, and 3 mg CUR or CUR-NP (containing 3 mg CUR). These micellar solutions were prepared in Dulbecco's Modified Eagle's Medium (DMEM) containing 15 mM sodium phosphate, 132 mM NaCl, 1% nonessential amino acid solution (100×, liquid), 1% penicillin/streptomycin/glutamine solution (100×, liquid), and 0.1% insulin solution (pH 7.4). The micelles 
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harigae et al prepared by sonication were centrifuged (100,000× g, 1 hour, 37°C). After the resultant suspension was filtered (Millex-GV, 0.22 μm, 33 mm) and gassed in an air and 5% CO 2 incubator for 2 hours to maintain pH 7.4 at 37°C, the concentration of CUR was analyzed by HPLC-UV as described earlier.
cell study
Caco-2 cells were grown in DMEM containing 10% fetal bovine serum (FBS), 1% nonessential amino acid solution, 1% penicillin/streptomycin/glutamine solution, and 0.1% insulin solution on 10 cm plastic petri dishes incubated at 37°C and 5% CO 2 . Cells were subcultured by removing the medium and detaching the cells from the culture dish using 0.05% trypsin in phosphate-buffered saline. Cells were suspended in 1.5 mL of culture medium and seeded on the apical side of Transwell ® (Corning Incorporated, Corning, NY, USA). Culture medium (2.5 mL) was added to the basolateral well. Cells were grown to confluency on the apical side for 15 days. After reaching confluency, cells were continuously cultured for 18 days to mature brush border membranes. Culture medium was changed every day.
The micelles (CUR-MM or NP-MM) obtained in the solubilization study were diluted with CUR-free micellar solutions and FBS to achieve the desired final concentration (25 μM CUR and 10% FBS in CUR-MM or NP-MM solutions). These sample micellar solutions (1.5 mL) were added to the apical side of differentiated Caco-2 cells. The basolateral side was filled with 2.5 mL of culture medium. After 3 or 24 hours of incubation, the medium was collected from both sides. The cells were scraped, collected, and subjected to sonication in 200 μL of water. The solution was then mixed with 400 μL of methanol, and the supernatant was collected after centrifugation (20, 000× g, 15 minutes, 4°C) . The supernatant was mixed with 1 mL of water. The culture medium (100 μL) was mixed with 500 μL of methanol and 1.4 mL of water. The mixture (1.6 mL for cells and 2 mL for medium) was loaded onto an Oasis HLB 1 cc cartridge, washed with 1 mL of water, and eluted with 2 mL of methanol. The extracts were dried and redissolved in 1 mL of methanol. Aliquots of the methanol extracts were analyzed by HPLC-MS/MS as described earlier. The procedures were performed in accordance with the Guidelines for Ethics Committee of Tohoku University.
statistical analysis
Data are expressed as mean ± standard error (SE). Statistical significance between the two groups was assessed by the Mann-Whitney U-test. Means significantly differed at P,0.05 and P,0.01.
Results

Nanoparticles characterization
After lyophilization of CUR-NP suspension, ~150 mg of CUR-NP powder was obtained. CUR-NP characteristics: mean diameter, 186.9±2.8 nm; PDI, 0.095±0.011; zeta potential, -16.7 mV; EE, 18.3%±1.1%; LE, 2.65%±0.09% (n=3). For a minimum of 3 months, the concentration of CUR in CUR-NP, its mean diameter, PDI, and zeta potential had not changed in the dark at -30°C (data not shown). Based on the SEM and TEM images of CUR-NP (Figure 1) , it appeared that CUR-NP was immobilized in the sucrose matrix without aggregation and around 200 nm spherical CUR-NP was confirmed by TEM with phosphotungstic acid staining. 
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Metabolic fate of Plga-based curcumin nanoparticles Dispersion of CUR-NP (lyophilized powder) in distilled water resulted in a homogeneous suspension (Figure 2) . These results indicate that CUR was successfully loaded into PLGA-based nanoparticles.
Metabolic fate of cUr-NP
Rats were divided into two groups and administrated orally with suspensions containing 100 mg/kg CUR or CUR-NP (at a dose equivalent to 100 mg CUR/kg). Figure 3 shows representative HPLC-MS/MS chromatograms of plasma extracts at 1.5 hours after oral administration of CUR or CUR-NP. The chromatogram contains two peaks: a large peak attributable to CURG and a small peak attributable to CUR. The maximum concentration (C max ) of CURG was 3,493±667 nM, and the time of maximum concentration (T max ) of CURG was 1.5 hours in the CUR-NP-administrated group (Figure 4) . The area under the blood concentration-time curve (AUC, calculated by GraphPad Prism 6 for Windows; GraphPad Software, Inc., La Jolla, CA, USA) of CURG in the plasma at 24 hours was significantly higher in the CUR-NP-administrated group compared with the CUR-administrated group ( Figure 5) . Additionally, other curcuminoids such as CURS, CURGS, DHCG, THCG, HHCG, DHCS, THCS, and HHCS were detected in the plasma, especially in the CUR-NP-administrated group ( Figure 6 ). We analyzed the curcuminoids in the livers and kidneys of rats 1.5 hours after oral administration of CUR or CUR-NP (Figure 7) .
In contrast to plasma samples, CURG was not detected in the liver. A small amount of CURG was detectable in the kidney with higher amounts in the CUR-NP-administrated group. Similar trends were observed for other metabolites in the liver and kidney (Table 1; Figure S1 ). However, there was no difference in the levels of CUR between the CUR-and CUR-NP-administrated groups. Taken together, these results suggest that CUR is effectively absorbed in rats following oral administration of CUR-NP and is present mainly as CURG in the plasma with minimal amounts found in other organs. Overall, encapsulating CUR with PLGA-based nanoparticles enhances the absorption of CUR.
Micellar solubilization and cell culture studies
For the micellar solubilization study, CUR-MM and NP-MM were prepared and the concentration of CUR in the mixed micelles was determined by HPLC-UV. NP-MM contained approximately three times the amount of CUR compared with CUR-MM (Figure 8 ). This suggests that CUR encapsulated in CUR-NP tends to be solubilized in mixed micelles. After adjusting the concentration of CUR in the CUR-MM and NP-MM solutions to 25 μM for the cell culture study, the solutions were added to the apical side of differentiated Caco-2 cells and incubated. HPLC-MS/MS analysis revealed that CUR and certain metabolites were present in the cells and medium ( Figure 9 ; Table 2 ). Some of the differences between CUR-MM-and NP-MM-treated groups were significant. However, the differences appeared to be small with the exception of CURS in medium (apical side) after 24 hours of treatment. Overall, these results suggest that the high solubilization capacity of CUR-NP in mixed micelles, rather than the cellular uptake efficiency, explains the high intestinal absorption of CUR-NP in vivo.
Discussion
Although CUR is known to exhibit antioxidative, antiinflammatory, antitumor, and lipid-lowering activities in vivo, it has limited bioavailability due to poor absorption and rapid metabolism and elimination. [1] [2] [3] [4] [5] [6] 22 A number of studies have suggested ways to overcome the inherent limitations of CUR. 23 For example, it has been suggested that encapsulation of CUR in PLGA-based nanoparticles increases the bioavailability of CUR by increasing intestinal permeability and reducing metabolic degradation and conversion to other metabolites. To the best of our knowledge, only four articles have reported the bioavailability of PLGA-based CUR-NP following oral administration. [14] [15] [16] 18 In these studies, PLGA-based CUR-NP was shown to increase the concentration of CUR in the plasma compared with aqueous suspensions of CUR. The results from these studies suggest that nanoparticles increase the relative bioavailability of CUR (comparing AUC/dose) by 5-to 26-fold. Thus, based on these previous studies, PLGA-based nanoparticles are expected to improve the bioavailability of CUR following oral administration. However, these studies have several limitations. For one, the reported CUR parameters [14] [15] [16] 18 (eg, C max , T max , and AUC) were variable.
More importantly, levels of CURG, which is the major metabolite found in the body, were not measured. Finally, it is unclear why encapsulating CUR with PLGA-based nanoparticles increases intestinal absorption. Overall, there is a lack of conclusive evidence that justifies the use of PLGA-based CUR-NP to enhance the absorption and bioavailability of CUR administered orally.
To provide conclusive evidence, we used rat in vivo and in vitro models to investigate intestinal absorption and metabolism of CUR-NP. We chose HPLC-MS/MS as the 
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Metabolic fate of Plga-based curcumin nanoparticles preferred analytical method because HPLC-MS/MS offers specific advantages over conventional analysis (HPLC-UV) of biomolecules. For instance, HPLC-MS/MS provides neutral loss scanning and MRM, which provides useful structural information even when background contaminants are present. 24 We and others have used HPLC-MS/MS with MRM to examine and identify several CUR metabolites in the plasma and tissues of rats and mice supplemented with CUR. 8, [25] [26] [27] [28] HPLC-MS/MS analyses of curcuminoids in liver microsomes and in turmeric have also been reported. 29, 30 In the present study, we used HPLC-MS/MS to analyze the number of curcuminoids (CUR, CURG, CURS, CURGS, CURDG, CURDS, DHC, THC, HHC, OHC, DHCG, THCG, HHCG, OHCG, DHCS, THCS, HHCS, and OHCS) present in the plasma and organs of rats. The detection of these curcuminoids by HPLC-MS/MS was reproducible and unaltered by the storage of extract samples at temperatures below -80°C for 1 month (data not shown). Based on these findings, rats were administrated orally with suspensions of either 100 mg/kg CUR or CUR-NP (at a dose equivalent to 100 mg CUR/kg). Abbreviations: cUr, curcumin; cUrg, curcumin glucuronide; cUr-NP, curcumin nanoparticles; cps, centipoise; cUrs, curcumin sulfate; cUrgs, curcumin glucuronide sulfate; Dhcg, dihydrocurcumin glucuronide; Thcg, tetrahydrocurcumin glucuronide; hhcg, hexahydrocurcumin glucuronide, Dhcs, dihydrocurcumin sulfate; Thcs, tetrahydrocurcumin sulfate; hhcs, hexahydrocurcumin sulfate; hPlc-Ms/Ms, high-performance liquid chromatography-tandem mass spectrometry; MrM, multiple-reaction monitoring.
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We subsequently analyzed CUR, CURG, and other metabolites in the plasma and organs by HPLC-MS/MS. The results suggest that CUR is effectively absorbed following oral administration of CUR-NP and is predominately found in the plasma as CURG (Figures 3-7 ; Table 1 ). Overall, CUR-NP increases intestinal absorption of CUR, but does not appear to prevent metabolic degradation and conversion to other metabolites (eg, glucuronidation). Although encapsulating CUR with PLGA-based NP improves intestinal absorption, there is still a need for formulations that improve resistance to metabolic degradation and conversion to other metabolites. The CUR-NP prepared in this study had a small diameter (186.9 nm), narrow size distribution (PDI =0.095), and negative zeta potential (-16.7 mV), which were similar to those reported in previous studies. [14] [15] [16] [17] [18] Some researchers have developed modified forms of PLGA-based CUR-NP. Tsai et al reported that using high-molecular-weight PLGA increases relative bioavailability of CUR 1.67-fold compared Figure 7 comparison of the concentration of cUr or cUrg in organs between cUr-and cUr-NP-administrated groups. Notes: concentration of (A) cUr in the rat liver, (B) cUr in the rat kidney, and (C) cUrg in the rat kidney at 1.5 hours following oral administration of cUr (100 mg/kg) or cUr-NP (at a dose equivalent to 100 mg cUr/kg) (mean ± se, n=4. Means significantly differed at *P,0.05, performed by Mann-Whitney U-test). Abbreviations: cUr, curcumin; cUr-NP, curcumin nanoparticles; cUrg, curcumin glucuronide; se, standard error. Notes: Peak areas of curcuminoids (except CUR and CURG) identified in rat liver and kidney are shown (mean ± se, n=4. Means significantly differed at *P,0.05, performed by Mann-Whitney U-test). The homogenized organ (100 μl) was extracted in 1 ml of methanol and 10 μl was analyzed by hPlc-Ms/Ms with MrM.
# representative chromatogram of Ohcs in rat liver at 1.5 hours following oral administration of cUr-NP is shown in Figure s1 . Abbreviations: cUr, curcumin; cUrg, curcumin glucuronide; cUr-NP, curcumin nanoparticles; se, standard error; hhcg, hexahydrocurcumin glucuronide; Thcs, tetrahydrocurcumin sulfate; hhcs, hexahydrocurcumin sulfate; Ohcs, octahydrocurcumin sulfate; nd, not detected; hPlc-Ms/Ms, high-performance liquid chromatographytandem mass spectrometry; MrM, multiple-reaction monitoring.
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harigae et al to low-molecular-weight PLGA. 17 Khalil et al reported that PLGA-polyethylene glycol nanoparticles increase CUR bioavailability by 55.4-fold compared to an aqueous suspension of CUR. 15 It is hypothesized that these formulations improve not only the absorbability, but also the resistance to metabolism of CUR. 23 Further studies are needed to improve the bioavailability of CUR. In addition, only a few studies have reported the presence of CUR metabolites other than CURG.
7,31-33 However, we revealed that other metabolites are present in the plasma and organs of rats following oral administration of CUR-NP ( Figure 6 ; Table 1 ). It would be interesting to see whether increased levels of CURG and other metabolites contribute to the physiological activity of CUR-NP.
In addition, the low EE may be due to aggregation during preparation. These aggregates appeared to be composed of larger-sized CUR-NP and CUR not wrapped in CUR-NP, and 
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Metabolic fate of Plga-based curcumin nanoparticles they were removed during centrifugation and filtration. Actually, during the solvent (dichloromethane) evaporation process, visible aggregates of CUR or CUR-NP were observed. Additional studies are needed to focus on optimizing the amounts of PLGA and PVA to overcome this problem. The mechanism of absorption of CUR in the gastrointestinal tract is still unclear. In the case of carotenoids, which exhibit chemical characteristics similar to those of CUR (eg, polarity and molecular weight), Yonekura et al reported that the absorption of dietary carotenoids involves several steps that begin with the mechanical and enzymatic disruption of the food matrix, release of the carotenoids, and the incorporation into the lipid droplets of gastric emulsions. 34 The carotenoids are then transferred from the lipid droplets to mixed micelles produced by the action of bile salts, biliary phospholipids, dietary lipids, and their hydrolysis products. Following solubilization, carotenoids are absorbed by the intestinal cells, packed into chylomicrons, and secreted into the lymphatic system. 35, 36 Therefore, the major factors that influence intestinal absorption of carotenoids are solubilization capacity in mixed micelles and their incorporation efficiency into intestinal cells, and these factors may be applicable to CUR.
Some studies have focused on the interaction between CUR and bile salts in mixed micelles. 37 Based on these studies, we prepared mixed micelles containing CUR or CUR-NP and compared the micellar solubilization to determine why CUR-NP has higher intestinal absorption ( Figure 5 ).
We found that NP-MM contained three times more CUR compared to CUR-MM (Figure 8 ), which suggests that encapsulated CUR enhances solubilization in mixed micelles. Therefore, we suggest that the high solubilization capacity of CUR-NP in mixed micelles results in higher intestinal absorption of CUR-NP in vivo.
We also investigated the cellular incorporation of these micelles into differentiated Caco-2 human intestinal cells, which are useful models for studying the absorption and metabolism of dietary compounds. 38, 39 We found that CUR and certain metabolites are present in the cells and medium ( Figure 9 ; Table 2 ). The levels of some of these metabolites were significantly different between the CUR-MM-and NP-MM-treated groups, but the differences appeared to be small, except for CURS in medium (apical side) after 24 hours of treatment. Taken together, these results suggest that the high solubilization capacity of CUR-NP in mixed micelles, rather than cellular uptake efficiency, explains the high intestinal absorption of CUR-NP in vivo. In addition, CUR in the medium (apical side) rapidly degraded ( Figure 9C ). These results are similar to previous studies [40] [41] [42] and most likely occurred due to rapid cellular uptake of CUR from the medium and/or CUR degradation in the medium.
40-42
Conclusion
We showed that CUR-NP administered orally to rats was effectively absorbed and the predominant CUR metabolite was CURG in the plasma. The results suggest that CUR-NP 
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harigae et al improves intestinal absorption, but does not improve metabolic degradation and conversion to other metabolites. The in vitro study revealed that CUR-NP is solubilized in mixed micelles and the high solubilization capacity of CUR-NP leads to higher intestinal absorption of CUR following oral administration. Since CURG is less potent in terms of antioxidant activity and antitumor effects compared to CUR, 8, 43 it is desirable to use a NP formulation that not only increases intestinal absorption but also decreases the metabolic degradation and conversion of CUR to other metabolites to further improve the bioavailability of CUR. Overall, additional in vitro and in vivo studies are needed to develop a better understanding of the absorption, metabolism, and overall effects of CUR and CUR-NP in the body.
